key: cord-0864446-j903dje2 authors: Schultheiss, Heinz-Peter; Baumeier, Christian; Pietsch, Heiko; Bock, C Thomas; Poller, Wolfgang; Escher, Felicitas title: Cardiovascular consequences of viral infections: from COVID to other viral diseases date: 2021-10-05 journal: Cardiovasc Res DOI: 10.1093/cvr/cvab315 sha: 2313d3a14cec7d84f91950ad1874399ff82fd5f3 doc_id: 864446 cord_uid: j903dje2 Infection of the heart muscle with cardiotropic viruses is one of the major etiologies of myocarditis and acute and chronic inflammatory cardiomyopathy (DCMi). However, viral myocarditis and subsequent dilated cardiomyopathy (DCM) is still a challenging disease to diagnose and to treat and is therefore a significant public health issue globally. Advances in clinical examination and thorough molecular genetic analysis of intramyocardial viruses and their activation status have incrementally improved our understanding of molecular pathogenesis and pathophysiology of viral infections of the heart muscle. To date, several cardiotropic viruses have been implicated as causes of myocarditis and DCMi. These include, among others, classical cardiotropic enteroviruses (coxsackieviruses B), the most commonly detected parvovirus B19, and human herpes virus 6. A newcomer is the respiratory virus that has triggered the worst pandemic in a century, SARS-CoV-2, whose involvement and impact in viral cardiovascular disease is under scrutiny. Despite extensive research into the pathomechanisms of viral infections of the cardiovascular system, our knowledge regarding their treatment and management is still incomplete. Accordingly, in this review we aim to explore and summarize the current knowledge and available evidence on viral infections of the heart. We focus on diagnostics, clinical relevance and cardiovascular consequences, pathophysiology, and current and novel treatment strategies. Infectious agents are the major causes of myocarditis and inflammatory cardiomyopathy (DCMi) [1] [2] [3] [4] . The clinical presentation is extremely heterogeneous, the natural history is unpredictable, and prognosis also varies according to the underlying etiology, environmental factors -most commonly initiated by a virus -and genetic predispositions 5, 6 . This fact, in conjunction to the lack of noninvasive specific diagnostic methods, makes it an underdiagnosed entity. To date, several cardiotropic viruses have been implicated as causes of myocarditis and DCMi. prompted the World Health Organization to declare COVID-19 a pandemic on 11th of March 2020. Epidemiological data from the present coronavirus pandemic demonstrate a significant relationship between COVID-19 and cardiovascular disease (CVD). Whether there is direct myocardial damage caused by SARS-CoV-2 or if it is primarily an endothelial disease is currently under investigation [10] [11] [12] [13] . A recent landmark study by Bailey et al. employing human autopsy tissues, human pluripotent stem cell-derived cardiomyocytes and engineered heart tissues has provided evidence that SARS-CoV-2 directly infects cardiomyocytes and does not infect cardiac macrophages, fibroblasts, or endothelial cells. They also found that infection of cardiomyocytes resulted in cytokine induction, sarcomere disassembly and cell death. Beyond a broad spectrum of previous clinical studies into the multiple other aspects of COVID-19, these data provide important additional insight into specific SARS-CoV-2 pathology within the heart 14 . To better understand the frequently unpredictable progression of viral myocarditis and DCMi, one has to address the underlying pathophysiological processes 15, 16 . Currently, there is consensus that both -immune-mediated and viral cytotoxic mechanisms -play a significant role in this regard. 7 . Beyond virus cytotoxicity, chronic immune stimulation or autoimmunity in DCMi results from incompletely cleared virus infection, or in response to the preceding virusor immune-mediated chronic tissue damage, respectively, even in the absence of infectious viral particles 5, 6 . It is considered possible that at some point in progression, multiple etiologic types confluence into a common autoimmune pathogenic process that leads to chronic inflammation, tissue remodeling, and fibrosis, ultimately progressing to the clinical phenotype of dilated cardiomyopathy (DCM). A consistent progression from myocarditis to DCM is described in about 30% of myocarditis patients. Any diagnostics started at this time often cannot elucidate the initial causes of the disease [17] [18] [19] [20] [21] [22] [23] . Understanding the underlying molecular mechanisms is required in order to be able to estimate the prognosis of the patients and is fundamental to proper management and specific treatments 19, 24 . Viral diagnostics and antiviral treatment should be started early before irreversible myocardial damage has developed 24, 25 . In this review, we discuss common viral infections and various stages of disease. We assess pathogenesis and mechanisms, clinical relevance and consequences, and outline patientspecific therapeutic options that are based on an accurate diagnosis, covering current and novel treatment strategies. SARS-CoV-2 is a is a novel coronavirus that was identified as the cause of COVID-19 in early 2020 (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses 26 ). Infection with SARS-CoV-2 can lead to viral pneumonia and acute respiratory distress syndrome (ARDS) and is accompanied by an increased risk of morbidity and mortality 27 . Besides respiratory complications, SARS-CoV-2 can trigger cytokine storm and coagulation abnormalities, leading to thromboembolic events up to multiorgan damage 13, 28 . Strikingly, there is a strong connection between CVD and severity of COVID-19. Initial clinical data suggested that both, susceptibility and clinical cause are highly dependent on cardiovascular comorbidities 29 . SARS-CoV-2 is a membrane-enveloped positive-sense, single-stranded RNA virus with a diameter of approx. 80-140 nm. Infection with human coronaviruses mainly results in respiratory and enteric diseases ranging from mild 'cold-like' symptoms up to severe life-threatening respiratory pathologies and lung injuries 26 . The infection of host cells with SARS-CoV-2 involves specific binding of viral spike (S) protein to the cellular entry receptor angiotensin-converting enzyme 2 (ACE2) 30 . In addition, fusion of viral particles is dependent on the proteolytic cleavage of the S protein by the host cell surface serine protease TMPRSS2. Host organism´s innate immune response plays a major role in the cause of COVID-19. Thus, several SARS-CoV-2 accessory proteins have been suggested to affect the innate immune response 31 . Abnormal pro-inflammatory cytokine levels and immune cell infiltration have been associated with the severity of tissue damage and morbidity of coronavirus infection 32, 33 . Aberrant infiltration of proinflammatory macrophages, cytotoxic T-cells and neutrophils has been observed in COVID-19 34, 35 . Thus, dysregulation of host immune response and elevated cytokine release seem to be crucial factors for the severity of COVID-19. A meta-analysis involving more than 6000 COVID-19 patients indicates an incidence of cardiac injury ranging from 15 to 42% depending on age and disease severity 36 . Post-mortem analysis of cardiac tissue of 39 patients who died as a consequence of coronavirus infection, revealed an incidence of 61.5% positive SARS-CoV-2 RNA detection in the heart 37 . A recent meta-analysis and literature screening revealed hypertension (28%), diabetes (14%) and CVD (12%) to be the most prevalent comorbidities in COVID-19 patients and thus, independent risk factors for mortality 38 . Moreover, a study including 40 SARS-CoV-2 positive patients confirmed the relationship between the presence of COVID-19 and acute cardiac damage 39 . However, whether cardiac injury is directly induced by SARS-CoV-2 infection is not clarified yet 40 . There are numerous hypotheses assessing the impact of SARS-CoV-2 infection on cardiovascular manifestations. These range from direct myocardial injury by disturbance of the ACE2 signaling, over systemic inflammatory damage (including cytokine storm) to cardiometabolic issues, arrhythmias and ischemia 12 . Infection has been proven for SARS-CoV-2 in cardiomyocytes and organoids 14 . Noteworthy, endotheliitis has been suggested to be involved in SARS-CoV-2 mediated cardiac damage 12, 41, 42 . A study on cardiac autopsy tissue from COVID-19 positive patients identified strong ACE2 / TMPRSS2 expression in capillaries of the heart and endotheliitis of small vessels with prevalence of CD4 + and CD68 + inflammatory cells 43 . Another post-mortem analysis of nine COVID-19 patients, who died due to cardiogenic shock, revealed the involvement of all compartments of the heart including intramural vessels, conduction tissue and subepicardial ganglia 44 . There is accumulating evidence that SARS-CoV-2 spike protein directly interacts with myocardial Toll-Like Receptor 4 (TLR4) leading to activation of the TLR4 signaling cascade (including pro-inflammatory cytokines and type I interferons) and even to upregulation of ACE2 surface expression 45 . First detection of SARS-CoV-2 genomes was provided in endomyocardial biopsies (EMBs) of patients with suspected myocarditis or unexplained heart failure 46 . Ultrastructural analysis of EMB of a 69-year-old patient positively tested for SARS-CoV-2 identified viral particles within the interstitial cells of the myocardium 47 . Cardiac magnetic resonance imaging in patients recently recovered from Sars-CoV-2 infection identified 78% with cardiac involvement and 60% with an ongoing myocardial inflammation 48 As known for other infectious diseases, SARS-CoV-2 is assumed to trigger acute coronary syndrome (ACS). However, the incidence of ASC in COVID-19 patients is still illusive and detailed mechanisms of SARS-CoV-2 contribution remain speculative. Putative involvement of COVID-19 in the development of ACS includes plaque rupture, coronary spasm or micro-thrombi induced by cytokine storm, and endothelial or vascular injury by direct infection of these cells with SARS-CoV-2 51 . Human parvovirus (B19V) genomes are the most frequently detected viral species in endomyocardial biopsies (EMBs) of patients with suspected heart failure ( Fig. 2) [52] [53] [54] . Infection with B19V can start during childhood and continues throughout adulthood, such that between 70-88% of adults show serologic evidence of past infections. B19V is a non-enveloped single stranded linear DNA virus of 20-24 nm in diameter. Its approximately 5.6 kb genome encodes for two major proteins, the NS1 protein (non-structural protein) and VP1/2 protein (capsid protein), and the small accessory 11 kDa and 7.5 kDa proteins of largely unknown function. The NS1 protein transactivates viral transcription and host genes, induces cell cycle arrest and DNA damage response, in order to facilitate viral replication and host cell apoptosis to release viral progeny 55, 56 . Various molecular mechanisms such as NS1 induced apoptosis may be responsible for direct cytotoxicity 57 . The association of myocardial B19V genome detection to heart diseases is still a matter of controversial discussion [58] [59] [60] . B19V DNA genomes were detected in approx. 73% of patients EMBs (Fig. 2 ) and were also found in 55% of healthy donor hearts suggesting no causal relationship 61 . However, these studies did not differentiate between latent (inactive) and transcriptional active (positive mRNA) viral infection. In contrast to latent B19V infection, expression of B19V viral mRNA and proteins in the myocardium was demonstrated to be of significance 62 , and replicative active B19V in the myocardium is related to adverse clinical outcome 53, 59 . We identified different cell types belonging to the heterogenous group of bone marrow-derived circulating angiogenic cells with similarities to endothelial and erythroid lineage, to be targets for B19V infection 63 . In chronic B19V-associated disease, cardiomyocytes, which are devoid of B19V receptors, are precluded from infection 64 Besides B19V, primary cardiotropic viruses are EV including Coxsackievirus B3 (CVB3) and echoviruses, ADV, the Herpesviridae genus such as HHV6, EBV, and CMV, all of which may cause or trigger myocarditis and DCMi 52,70 (Fig. 2) . Influenza-(IAV/IBV), HCV and HIV infections are associated with an increased incidence of cardiac complications [71] [72] [73] . In addition to the cardiotropic viruses mentioned above, there are sporadic reports, most often as case reports, identifying varicella zoster virus (VZV), Zika virus (ZIKV), Dengue virus (DENV) and Chikungunya virus (CHIKV) being linked to viral myocarditis. Similar observations have been made for rabies, rubella, mumps, and measles virus 8 . In general, proof of viral genomes in the myocardium is independent from the severeness of myocardial dysfunction 74 . Whether all of these viruses can be causative for the development of viral myocarditis or just being an incidental finding has to be determined. EV (Picornaviridae) are small, single-stranded, positive-sense RNA viruses. Non-enveloped EV are common human pathogens responsible for lower and upper respiratory tract infections that are transmitted via the fecal-oral route targeting the heart secondarily. 20 years ago, frequency of enteroviral infection accounts for up to 10% of heart failure patients who underwent EMB. However, recent studies report less frequent finding of CVB-3 which might be associated with regional and temporal patterns 75, 76 . EV and ADV enter cardiomyocytes via binding the transmembrane coxsackievirus and adenovirus receptor (CAR), which represents a potential antiviral target 77, 78 . Direct cardiac damage during acute phase is a consequence of viral replication and impaired cellular translation, induction of apoptosis, and oxidative stress followed by cell lysis 77, 79, 80 . During subacute phase of CVB-3 infection, an unbalanced immune response and immune-mediated destruction of cardiac tissue or induction of autoimmune processes may occur 81, 82 . EV persistence in the myocardium is associated to a significant higher mortality 83 . Genotyping revealed a strong correlation between the CCR5 mutation and spontaneous virus clearance with improved outcomes 84 . During the chronic phase, CVB-3 might be eliminated or viral persistence may result in the progression to DCM characterized by cytoskeletal disruption and compromised contractility often associated with virus mediated immune response 82, 85 (Fig. 3 ). HHV6 (subtype A and B), as the most frequently found herpesvirus in the myocardium ( Only few case reports describe findings of CMV, EBV, and VZV in the myocardium that are associated with a pathological phenotype 70, 91, 92 . Molecular mechanism of CMV and EBV infection of the myocardium remain to be elucidated, however pathophysiological effects most probably result from immune-mediated damage or endothelial dysfunction as a consequence of CMV replication (Fig. 3 ). Accumulating evidence suggests that HCV, a globally widespread RNA virus that mainly affects the liver, may also play a role in the pathogenesis of heart diseases including myocarditis and DCM 73, 93 . Besides hepatitis C, chronic HCV infection is associated with various extrahepatic manifestations, like glomerulonephritis, myositis, and others. Extrahepatic manifestations are believed to be due to the lymphotropism of HCV with accumulation of circulating immune complexes, modulation of host immune response, and activation of autoimmune responses 94 . In recent multicentric studies, Matsumori et al. identified a significant higher seroprevalence of anti-HCV antibodies in patients suffering from myocarditis, DCM, and heart failure than in the general population. Additionally, HCV RNA genomes could be also detected in anti-HCV positive sera and EMBs from patients with myocarditis and DCM 73, 95 . The pathogenesis of HCV-induced myocarditis and DCM is still poorly investigated; however, a recent study provides evidence that of mononuclear cells a major target of HCV could be leukocytes and especially CD68 positive monocytes/macrophages 96 . These cells induced by HCV infection may cause inflammation in the organs including the heart muscle leading to myocarditis, DCM, and other cardiomyopathies. The initial evaluation of acute myocarditis and DCMi includes a detailed history and physical examination in which possible features suggestive of etiology may provide clues. Cardiac serum biomarkers, specifically troponin I and troponin T, can help to confirm the diagnosis, but lack sensitivity. Other inflammatory serum markers, including white blood cell count, erythrocyte sedimentation rate, and C-reactive protein levels, may be elevated in acute myocarditis, but are neither sensitive nor specific in terms of determining the presence or absence of active myocardial inflammation with or without viral infection 8, 99 . Serologic testing has often been used in the past to identify pathogens in viral myocarditis. However, these methods lack direct correlation between viral infection and myocarditis 9,100 . including ST-segment elevation mimicking acute myocardial infarction. However, these changes are neither sensitive nor specific for the diagnosis of myocarditis and DCMi. Echocardiography is a valuable tool in detecting global or regional wall motion abnormalities, with myocardial strain patterns adding a special value 9 . Magnet resonance imaging (MRI) with extracellular contrast agent can be valuable for mapping tissue hyperemia associated with the intense inflammatory response of acute myocarditis. Imaging techniques such as MRI provide accurate noninvasive tissue characterization but not genesis clarification of an infectious agent because they cannot detect or quantify different viral types and loads or subtypes of immune response 101 . EMB is the gold-standard method to distinguish directly infectious agent-mediated from multiple types of immune-mediated injury of tissue and can provide specific etiologic information with significant consequences for management and differential therapy 1, 8, 9, 99 The expression of eight miRNAs was significantly increased in samples from patients with advanced heart failure and viral persistence with or without inflammation 108 . Thus, miRNAs can serve as a non-invasive, additional tool for indication of EMB decision making. Symptomatic heart failure therapy may improve clinical symptoms and hemodynamic situation. However, a specific antiviral or anti-inflammatory therapy is not covered by this 16 . Several antiviral therapies are currently being investigated for patients with COVID-19, including strategies to prevent viral entry into the host cell (e.g., chloroquine, hydroxychloroquine), protease inhibitors (lopinavir-ritonavir and darunavir), RNA polymerase inhibitors (remdesivir), and anti-cytokine agents (e.g., IL-6 receptor antagonists), all of which relate to general treatment strategies 109 . Negative results were obtained for clinical trials of newly developed HIV protease inhibitors such as lopinavir/ritonavir (Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial) and darunavir/cobicistat for COVID-19, with no significant impact on mortality or length of hospital stay. 110 . Clinical trials with ribavirin against MERS showed high levels of toxicity. 111 . In a phase 3 clinical trial, remdesivir was not associated with clinical improvement 112 . Spontaneous enteroviral clearance is associated with significant improvement of LVEF while persistence leads to progressive heart failure and is associated with significantly higher risk of death 16, 76 . A non-randomized study was started treating EV and ADV positive patients with interferon-ß (IFN-ß). Upon IFN-ß treatment complete elimination of EV and ADV genome was proved by follow-up EMBs after finishing of the anti-viral therapy 83 . Virus clearance was paralleled by an improvement of mean LVEF and an amelioration of heart failure symptoms and improvement of survival. Thereafter, a Phase 2 studybetaferon in a chronic viral cardiomyopathy (BICC)-trial was initiated 116 . Patients with symptoms of heart failure and biopsy proven EV, ADV, and/or B19V genomes were randomly assigned to double-blinded treatment. Compared to the placebo, virus elimination and/or virus load reduction was higher in the IFN-ß groups. IFN-ß treatment was associated with significant improvement on NYHA functional class improvement and in quality of life. IFN β treatment has proven less effective in clearing B19V infection. However, no differentiation between latent B19V infection and viral transcriptional activity was made in this study. In a pilot study, endothelial dysfunction improved with treatment of IFN-ß due to suppression of viral replicative intermediates, suggesting that this treatment option may improve endothelial viability 64 . Innovative therapy and prevention strategies to control B19V transcriptional activity are currently under investigation. Telbivudine is an antiviral nucleoside analog reverse transcriptase inhibitor with pleiotropic immunomodulatory effects that has been described to be effective in retroviral and pararetroviral (hepatitis B virus) infections by preventing dysregulation of BIRC3 and thus suppresses induction of apoptotic pathways 117 . Clinical improvement and reduction of transcriptional activity has been shown after Telbivudine treatment in a non-randomized study 118 . Intravenous immunoglobulin (IVIg) therapy did not result in clinical improvement of B19V-associated chronic DCM, however, transcriptional activity was not evaluated 119 . Patients with HIV-associated myocarditis or DCMI are treated by antiretroviral therapy with clear survival benefits although with cardiac side effects of medication 120, 121 . Patients with HCV-associated myocarditis or inflammatory cardiomyopathy were treated by combination therapies employing ombitasvir, paritaprevir, ritonavir, and dasabuvir 71, 122 . Treatment with aciclovir, ganciclovir, or valaciclovir might be considered for herpesvirus infections, although their efficacy has not been directly evaluated in patients with myocarditis. Persistently high loads of HHV6 genomes in blood cells or tissues confirm the presence of ciHHV6. Elimination of the chromosomally integrated virus is impossible, but the transcriptional activity of ciHHV6 may be reduced by treatment with valganciclovir 90 . Myocardial inflammation or systemic autoimmunity persisting despite virus elimination warrants immunosuppressive treatment, in order to prevent later immune-mediated myocardial injury. However, viral genomes have to be excluded prior to immunosuppressive therapy as analysis of patients with DCMi showed that patients with persistent viruses did not improve or even deteriorated upon immunosuppressive therapy, while virus-negative patients improved significantly 123, 124 . Treatment approaches for these patients with post infectious chronic myocarditis/inflammatory cardiomyopathy consist of corticosteroids, azathioprine, or ciclosporin A, in addition to optimal heart failure medication 125 . TH17 cell response seems to be one of the keys in the progression to chronic damage, cardiac fibrosis and loss of cardiac function in autoimmune processes 5 . The potential of an anti-Interleukin 17 therapy still needs to be evaluated. The phase 3, multicenter double-blind, placebo-controlled, randomized-withdrawal study RHAPSODY provided evidence of the potential efficacy and safety of rilonacept, an interleukin-1α and β inhibitor in chronic pericarditis 126 . This agent may also be considered as a potential therapeutic option for post-viral inflammation processes. Whereas conventional antiviral vaccine development methods 127 Whereas prophylaxis was and will of course always be superior to any possible treatment, a spectrum of novel nucleic acid-based therapeutics against molecular targets that cannot be sufficiently or optimally addressed using traditional small molecule drugs or antibodies, has recently successfully entered the clinical arena. In the field of cardiovascular medicine 137 It is also important to note that the incidence of cardiovascular/myocardial infections with several viruses is known to be highly variable over decades. Since detection of myocardial viral infections is far more difficult compared to systemic ones, this epidemia-like rise and fall of viruses such as CVB3 could only be detected by large-scale in-depth myocardial diagnostics which are not commonly conducted 76 . This is an unfortunate situation since at times CVB3 or adenoviruses caused a large fraction of all heart failure cases among children and adults, whereas their incidence is currently low. Conversely, if a large epidemic or even pandemic with a highly cardiotropic virus "free" of systemic signs on infection would be rapidly spreading, clinical recognition of this wave could be critically delayed until a rather high number of heart failure cases arises in a population without recognizable risk factors. In fact, this was the way by which the first viral myocarditis/heart failure "outbreak" with CVB3 was discovered in the small Midwestern city of Coxsackie. On the other hand, recent CRISPR-based technological breakthroughs including massively multiplexed nucleic acid detection using the CARMEN-Cas13 system 139 now enable more comprehensive virome screening than prior PCR-based approaches. Relevance of miRNAs for the clinical course of infections has also been documented for human cardiomyopathies associated with B19V 156 or CVB3. In the latter, differential cardiac miRNA expression closely predicted the clinical course. The most highly expressed miRNAs associated with rapid progression and an adverse outcome could possibly constitute RNAi targets. Remaining challenges: We recently discussed that the high potential of CRISPR and other nucleic acid drugs needs to be weighed against potential risks, but from the clinical practice viewpoint the delivery issue of the nucleic acid drugs to target organs is only partially solved. Current nanoparticle vehicles employing the Gal-NAc system have efficiently delivered ASO and RNAi drugs to the liver as documented in several landmark trials in the cardiovascular field 137 . Progress has also been achieved towards aerosol delivery of nucleic acid drugs to the lung including a combination treatment using an inhalable GapmeR oligonucleotide and recombinant ACE2 for COVID-19 157, 158 . Biologically efficient delivery of nucleic acid therapeutics (siRNAs) to the myocardium has been achieved by recombinant expression from AAV viral vectors in animal models 159, 160 . Whereas this delivery approach has not yet entered the clinical arena 161, 162 . AAV-based as well as nonviral delivery of a broad spectrum of novel antiviral nucleic acids drugs would thus become available for treatment trials of viral cardiomyopathies. In summary and synopsis with a recent comprehensive review by Le et al. 163 on nucleic acid-based technologies targeting coronaviruses, it is evident that possible clinical success of any nucleic acid drug is critically dependent on the technological challenge of efficient and focused drug delivery. Importantly, the above new therapeutic approaches offer extremely high versatility to adapt to essentially any coding or non-coding, viral or host cell, molecular target. Further, their largescale production will follow similar (i.e. RNA, DNA, XNA) synthetic pathways, enabling massive up-scaling of therapeutics production if required. The current pandemic, originating from transmission of a mutated animal virus to man, has heightened concerns and awareness that amongst the vast number of animal viruses others may cross the species barrier to humans 164, 165 . Therefore, foresighted expansion of our antiviral arsenal appears warranted. The combination of genetic factors that increase susceptibility to cardiomyopathy combined with acquired causes of cardiomyopathy, such as viral infection and/or autoimmunity, may be an explanation for the variable penetrance and severity of DCMi. The availability of novel techniques and novel insights into pathophysiology will help to address knowledge gaps in the future. Efficacy of therapeutic approaches needs to be evaluated in large, controlled, randomized trials to facilitate the development of personalized treatment options. Coxsackievirus B3 (CVB-3) and adenovirus (ADV) enter cardiomyocytes via binding the transmembrane coxsackievirus and adenovirus receptor (CAR). In addition, decayaccelerating factor (DAF) serves as CVB-3 receptor. Integrins (αvβ3 and αvβ5) promote ADV internalization. Parvovirus B19 (B19V) targets endothelial cells by binding to erythrocyte P antigen (P-Ag) and integrin αvβ1 as co-receptor. Epstein Barr-virus (EBV) efficiently infects resting human B lymphocytes, whereas human herpesvirus 6 (HHV6) primarily targets CD4+ T lymphocytes. Using CD46 as cellular receptor, HHV6 can directly infect endothelial cells and subsequently enter adjacent tissues. SARS-CoV-2 cellular entry involves specific binding to the angiotensin-converting enzyme 2 (ACE2) receptor as well as proteolytic cleavage by the host cell surface serine protease TMPRSS2. For SARS-CoV-2, several cardiac targets including vascular endothelial cells and cardiomyocytes are proposed. Moreover, pulmonary derived macrophages are suggested carrying the virus into the myocardium. As a consequence of viral infection, Toll-Like Receptor (TLR) 3, 4, 7, 8 and 9 signaling cascade is initiated, followed by infiltration of several inflammatory cells including T and B lymphocytes, natural killer (NK) cells and bone-marrow derived monocytes, which differentiate into M1 and M2 macrophages. B19V infection can be differentiated into latent infection without myocardial damage and active infection characterized by VP1 and/or NS1 mRNA detection. The later can result in severe endothelial dysfunction, followed by immune cell infiltration and development of myocarditis or inflammatory cardiomyopathy (DCMi). Abbreviations: ss = single stranded; ds = double stranded. Decades after similar work on CVB3 myocarditis in humans, this paper dealing with SARS-CoV-2 finds similarly restricted cellular tropism (cardiomyocytes but not cardiac macrophages, fibroblasts, or endothelial cells) and mechanistic sequelae of SARS-CoV-2 infection (innate immune activation with cytokine induction, sarcomere disassembly, and cell death). Whereas recombinant AAV vectors (to the right) were successfully employed for RNAi and anti-miR therapy of myocardial disorders in animal models, this approach has not yet entered the clinical arena. Global efforts, significantly driven by the current pandemic, are currently being devoted to fully exploit the clinical potential of these new antiviral strategies European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Dilated cardiomyopathy Cardiac autoimmunity: Myocarditis Myocarditis evolving in cardiomyopathy: when genetics and offending causes work together Viral myocarditis The spectrum of myocarditis: from pathology to the clinics Myocarditis in Clinical Practice Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review COVID-19 and Cardiovascular Disease: From Bench to Bedside COVID-19 -A vascular disease Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis The management of myocarditis Dilated cardiomyopathy update: infectious-immune theory revisited The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies Unresolved issues in theories of autoimmune disease using myocarditis as a framework Inflammation in viral myocarditis: friend or foe? Molecular Biology and Pathogenesis of Viral Myocarditis Republished: pathogenesis and diagnosis of myocarditis Myocarditis: treatment of myocarditis Myocarditis: early biopsy allows for tailored regenerative treatment The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study The trinity of COVID-19: immunity, inflammation and intervention Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2 Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis Prevalence and impact of cardiac injury on COVID-19: A systematic review and meta-analysis Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. Mallhi TH Myocardial involvement in coronavirus disease 19 The Heart in COVID-19: Primary Target or Secondary Bystander? JACC Basic to COVID-19 is, in the end, an endothelial disease COVID-19-associated vasculitis and vasculopathy SARS-CoV-2 leads to a small vessel endotheliitis in the heart Virus-Negative Myopericarditis in Human Coronavirus Infection: Report From an Autopsy Series COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies Myocardial localization of coronavirus in COVID-19 cardiogenic shock Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection Endothelial cell infection and endotheliitis in COVID-19 High prevalence of viral genomes and multiple viral infections in the myocardium of adults with 'idiopathic' left ventricular dysfunction A distinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells Human parvovirus B19 non-structural protein (NS1) induces apoptosis through mitochondria cell death pathway in COS-7 cells Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure Human Parvovirus B19-Associated Myocarditis Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature Parvovirus B19 in Endomyocardial Biopsy of Patients With Idiopathic Dilated Cardiomyopathy: Foe or Bystander? parvovirus mRNAs as markers for viral activity in endomyocardial biopsy-based diagnosis of patients with unexplained heart failure Impaired Endothelial Regeneration Through Human Parvovirus B19-Infected Circulating Angiogenic Cells in Patients With Cardiomyopathy Interferon Beta Modulates Endothelial Damage in Patients with Cardiac Persistence of Human Parvovirus B19 Infection Human Parvovirus B19 (B19V) Up-regulates CXCR4 Surface Expression of Circulating Angiogenic Cells: Implications for Cardiac Ischemia in B19V Cardiomyopathy Immunohistological detection of Parvovirus B19 capsid proteins in endomyocardial biopsies from dilated cardiomyopathy patients Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease A Novel Murine Model of Parvovirus Associated Dilated Cardiomyopathy Induced by Immunization with VP1-Unique Region of Parvovirus B19 Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults High incidence of cardiac dysfunction and response to antiviral treatment in patients with chronic hepatitis C virus infection Biopsy-proven autoimmune myocarditis in HIV-associated dilated cardiomyopathy Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation United States High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With "Idiopathic" Left Ventricular Dysfunction Enterovirus Persistence in Cardiac Cells of Patients With Idiopathic Dilated Cardiomyopathy Is Linked to 5' Terminal Genomic RNA-Deleted Viral Populations With Viral-Encoded Proteinase Activities Viral persistence in the myocardium is associated with progressive cardiac dysfunction Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction A Kidnapping Story: How Coxsackievirus B3 and Its Host Cell Interact Coxsackievirus B3 replication and pathogenesis Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis Viruses as adjuvants for autoimmunity: Evidence from Coxsackievirus-induced myocarditis Interferon-Beta Improves Survival in Enterovirus-Associated Cardiomyopathy CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5 Recent progress in understanding coxsackievirus replication, dissemination, and pathogsenesis Human herpesvirus 6 Aggravation of left ventricular dysfunction in patients with biopsy-proven cardiac human herpesvirus A and B infection Detection of parvovirus B19 and human herpesvirus 6 in pediatric dilated cardiomyopathy: Impact after heart transplantation Differential aspects of endothelial function of the coronary microcirculation considering myocardial virus persistence, endothelial activation, and myocardial leukocyte infiltrates Chromosomally integrated human herpesvirus 6 in heart failure: prevalence and treatment Ventricular Fibrillation following Varicella Zoster Myocarditis. Case reports Cardiol Cytomegalovirus Infection of the Heart Is Common in Patients with Fatal Myocarditis Hepatitis C Virus-Associated Extrahepatic Manifestations in Lung and Heart and Antiviral Therapy-Related Cardiopulmonary Toxicity Extrahepatic manifestations of chronic HCV infection Myocarditis and heart failure associated with hepatitis C virus infection Diagnosis and treatment of HCV heart diseases Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document Clinical presentation and diagnosis of myocarditis The Diagnosis and Evaluation of Dilated Cardiomyopathy Virus serology in patients with suspected myocarditis: utility or futility? Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology Diagnostic use of the endomyocardial biopsy: a consensus statement Identification of potential pathogenic viruses in patients with acute myocarditis using next-generation sequencing Absent MicroRNAs in Different Tissues of Patients with Acquired Cardiomyopathy MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis MicroRNA profiling as a novel diagnostic tool for identification of patients with inflammatory and/or virally induced cardiomyopathies Differential Cardiac MicroRNA Expression Predicts the Clinical Course in Human Enterovirus Cardiomyopathy Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy Telbivudine Reduces Parvovirus B19-Induced Apoptosis in Circulating Angiogenic Cells Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research HIV-1-Related Cardiovascular Disease Is Associated With Chronic Inflammation, Frequent Pericardial Effusions, and Probable Myocardial Edema Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273 On the Shoulders of Giants -From Jenner's Cowpox to mRNA Covid Vaccines Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination A Novel Coronavirus from Patients with Pneumonia in China Global absence and targeting of protective immune states in severe COVID-19 COVID-19: A review of therapeutic strategies and vaccine candidates From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza targeted siRNA-nanoparticle therapy for COVID-19 siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5'UTR of SARS-CoV-2 In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs Cardiovascular RNA interference therapy: the broadening tool and target spectrum Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure Combination of soluble coxsackievirus-adenovirus receptor and anticoxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3 Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice Inhibition of adenovirus infections by siRNAmediated silencing of early and late adenoviral gene functions The genome of human parvovirus b19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus Single-target RNA interference for the blockade of multiple interacting proinflammatory and profibrotic pathways in cardiac fibroblasts Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor The SARS-CoV-2 RNAprotein interactome in infected human cells Non-Coding RNAs and SARS-Related Coronaviruses miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery miRNA as activity markers in Parvo B19 associated heart disease Antisense technology: an overview and prospectus Review of the Technical, Toxicological, and PKPD Considerations for Conducting Inhalation Toxicity Studies on Biologic Pharmaceuticals-The Outcome of a Cross-Industry Working Group Survey Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy Next-generation AAV vectors-do not judge a virus (only) by its cover New therapeutics targets in chronic viral cardiomyopathy AntimiR-21 Prevents Myocardial Dysfunction in a Pig Model of Ischemia/Reperfusion Injury Nucleic Acid-Based Technologies Targeting Coronaviruses Emerging Pandemic Diseases: How We Got to COVID-19 Origin and crossspecies transmission of bat coronaviruses in China None declared.